Chemotherapy for carcinomatous peritonitis and pleuritis with MMC-CH, mitomycin C adsorbed on activated carbon particles. Clinical trials

Abstract

A new drug dosage form comprising activated carbon particles adsorbing mitomycin C (MMC-CH) is designed to slowly release its components, and has affinity for the tumor surface and lymph nodes and a tendency to stay long in the local portion. The therapeutic index of MMC-CH in experimental carcinomatous peritonitis is 3.1 times as high as that of MMC-solution. In clinical experiments 81 patients with carci-nomatous effusions were administered with MMC-CH (2.0-2.4 mg/kg in terms of MMC) in bolus in-tracavitarily. Fifty-one patients responded well to the MMC-CH therapy. Nineteen patients were alive for more than 6 months. The responders showed marked improvement in subjective symptoms, and 26 patients became dischargeable from hospital. Bone marrow suppression and peritoneal irritation were main adverse effects, but the symptoms were temporary and not so serious in spite of a high dose of MMC. Cancer 59:245-251, 1987. OR CARCINOMATOUS peritonitis or pleuritis, many F kinds of anticancerous agents in solution form have been administered intracavitarily. These methods are not always successful to control the local lesion, because therapeutic agents injected intracavitarily in solution form are easily absorbed through the large serosal surface into blood plasma and it is difficult to keep a high concentration of the agents for a long time in the ~ a v i t y. ~ To surmount this difficulty we have decided to utilize the functional slow-releasing ability of adsorbents, and devised a new dosage form, called MMC-CH,6 comprising fine activated carbon particles adsorbing mitomycin C (MMC). Experiments with animals have shown that MMC-CH slowly releases its components, and has affinity for the tumor surface and lymphatics, and a tendency to stay long in the cavity. Rat experiments indicate that MMC-CH has higher therapeutic effects on experimental carcinomatous peritonitis than MMC-solution.

Preparation of a Conjugate of Mitomycin C and Anti-Neural Cell Adhesion Molecule Monoclonal Antibody for Specific Chemotherapy Against Biliary Tract Carcinoma

“…To overcome these drawbacks, the targeting of anticancer drugs with various types of drug carriers has thus been investigated. [12][13][14] With the advent of monoclonal antibody technology, the use of antibodies as carriers of pharmacological agents has become more practical, and several studies have therefore demonstrated the potential clinical feasibility of immunoconjugates. 4,15 The main factors allowing a MoAb and anti-cancer drug conjugate to be effective on cancer cells are their high cytotoxic potency and a high selective binding activity of the immunoconjugates to the target cancer cells.…”

Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis

“…Up to now, most oncologists would regard them as a situation only to be palliated. Intraperitoneal injection of anticancer drugs, such as OK 432 4 or mitomycin C (MMC) absorbed on activated charcoal, 5 has been used, but the effectiveness of this approach has not been well established. Research protocols, including immediate postoperative intraperitoneal chemotherapy and extended peritonectomy, 6 are currently ongoing.…”

Receptor binding assays in analysing the bioavailability and pharmacodynamic bioequivalence of active drug moieties

“…order to obtain the best fit for the estimates of K D and K i. The values obtained (Table 1) were in conformity with those reported in the literature [9,11,13,14].…”

“…In the sustained-release formulation the drug was preadsorbed onto 120 mg activated charcoal [11,12].…”